STK11 and non-small cell lung carcinoma: These findings identify a metabolic vulnerability specific to KRAS/LKB1 co-mutant tumors within the HBP and propose the targeting of PGM3 as a potential therapeutic strategy for this aggressive subtype of NSCLC.